Results 21 to 30 of about 42,523 (291)

Buprenorphine versus dihydrocodeine for opiate detoxification in primary care: a randomised controlled trial [PDF]

, 2007
Background Many drug users present to primary care requesting detoxification from illicit opiates. There are a number of detoxification agents but no recommended drug of choice. The purpose of this study is to compare buprenorphine with dihydrocodeine
A Davies, A Glanz, A Masson, A Nigam, C de Wet, Charlotte NE Tompkins, Clive E Adams, D van der Windt, D Zador, E Ward, G Fischer, H Swadi, J Banbery, J Hetherton, J Lowinson, J MacLeod, J Seifert, J Strang, K Carrol, K Fairhurst, L Cheskin, L Sheard, Laura Sheard, M Ashton, M Gossop, N Lintzeris, N Seivewright, N Wright, Nat MJ Wright, National Treatment Agency, Nicola S Oldham, P O'Connor, P Pani, R Horton, R Johnson, R Mattick, R Robertson, R White, Royal College of General Practitioners, S Petitjean, S Simoens, S Vanichseni, T Kosten, Victoria L Allgar, W Bickel, W Ling   +45 more
core   +3 more sources

The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) project: An open-label pragmatic randomised control trial comparing the efficacy of differing therapeutic agents for primary care detoxification from either street heroin or methadone [ISRCTN07752728] [PDF]

, 2004
BACKGROUND: Heroin is a synthetic opioid with an extensive illicit market leading to large numbers of people becoming addicted. Heroin users often present to community treatment services requesting detoxification and in the UK various agents are used ...
A Ritter, Advisory Council on the Misuse of Drugs, AH Masson, AK Nigam, Charlotte NE Tompkins, Clive E Adams, E Goddard, Great Britain Department of Health, Great Britain Government Statistical Service, Home Office, J Lowinson, J Strang, J Strang, L San, Laura Sheard, LJ Cheskin, M Ramsay, N Linteris, N Seivewright, Nat MJ Wright, Nicola S Oldham, PG O'Connor, Royal Pharmaceutical Society of Great Britain, WK Bickel   +22 more
core   +3 more sources

Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine‐maintained heroin users [PDF]

Addiction Biology, 2014
AbstractIn spite of the clinical utility of buprenorphine, parenteral abuse of this medication has been reported in several laboratory investigations and in the real world. Studies have demonstrated lower abuse liability of the buprenorphine/naloxone combination relative to buprenorphine alone.
Verena E. Metz, Shanthi Mogali, Suzanne K. Vosburg, Jeanne M. Manubay, Jermaine D. Jones, Maria A. Sullivan, Sandra D. Comer   +6 more
openaire   +2 more sources

The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project pilot study: protocol for a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification [PDF]

, 2007
Background In the United Kingdom (UK), there is an extensive market for the class 'A' drug heroin. Many heroin users spend time in prison. People addicted to heroin often require prescribed medication when attempting to cease their drug use.
Adams, C.E., Dalton, R., El-Sayeh, H., Sheard, L., Tompkins, C.N.E., Wright, N.M.J.   +5 more
core   +2 more sources

Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report [PDF]

Mental Health Clinician, 2021
Background Buprenorphine is a partial mu-opioid receptor agonist approved for the treatment of opioid dependence. The risk of withdrawal symptoms and wait time required to safely initiate buprenorphine provides challenges to both patients and providers ...
Menard Shannon PharmD, Jhawar Archana PharmD, BCPP   +1 more
doaj   +1 more source

Emergency Department Clinicians’ Attitudes Toward Opioid Use Disorder and Emergency Department-initiated Buprenorphine Treatment: A Mixed-Methods Study [PDF]

, 2020
Introduction: Emergency department (ED) visits related to opioid use disorder (OUD) have increased nearly twofold over the last decade. Treatment with buprenorphine has been demonstrated to decrease opioid-related overdose deaths. In this study, we aimed
Carlson, Lucas C., Chary, Anita, Condella, Anna L., Im, Dana D., Kunzler, Nathan, Martin, Alister, Samuels-Kalow, Margaret, Vogel, Lara, Vongsachang, Hurnan, Weiner, Scott G.   +9 more
core  

Community pharmacy attitudes and behaviors following a buprenorphine best practices dissemination [PDF]

Mental Health Clinician
Introduction: Opioid overdose deaths continue to rise despite available safe and efficacious treatments for opioid use disorder, such as buprenorphine. Whereas provider-level access to buprenorphine has improved, community pharmacy-level barriers remain,
Winter Roth, PharmD, BCPP, David Dadiomov, PharmD, BCPP   +1 more
doaj   +1 more source

Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin‐evoked dopamine release in rats

Neuropsychopharmacology Reports, 2020
Aims The United States of America is currently in an opioid epidemic. Heroin remains the most lethal opioid option with its death rate increasing by over 500% in the last decade.
Dominic P. Isaacs, Ryan P. Leman, Thomas J. Everett, Hendrick Lopez‐Beltran, Lindsey R. Hamilton, Erik B. Oleson   +5 more
doaj   +1 more source

Buprenorphine for Opioid Use Disorder in the Emergency Department: A Retrospective Chart Review

Western Journal of Emergency Medicine, 2020
Introduction: Emergency care providers routinely treat patients with acute presentations and sequelae of opioid use disorder. An emergency physician and pharmacist implemented a protocol using buprenorphine for the treatment of patients with opioid ...
Kathy T. LeSaint, Brent Klapthor, Ralph C. Wang, Curtis Geier   +3 more
doaj   +1 more source

Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018

Addiction Science & Clinical Practice, 2022
Background Medications to treat opioid use disorder (OUD) including buprenorphine products are evidence-based and cost-effective tools for combating the opioid crisis.
Kevin P. Conway, Dalia Khoury, Rainer Hilscher, Arnie P. Aldridge, Stephanie J. Parker, Gary A. Zarkin   +5 more
doaj   +1 more source